Navigation Links
EpiCept Releases New Data Demonstrating Prolonged Five-Year Leukemia-Free Survival for AML Patients Treated with Ceplene(TM) + IL-2
Date:12/9/2007

se among AML patients. These data were presented by Ana I. Romero from the Department of Internal Medicine, University of Goteborg in a presentation entitled, "Histamine Dihydrochloride Maintains Cytoxic Effector T Lymphocyte Function and Viability under Conditions of Oxidative Stress."

In the study, researchers recovered autoreactive T-cells from AML patients and exposed them to exogenous hydrogen peroxide or oxygen radical-producing mononuclear phagocytes. Ceplene, an inhibitor of oxygen radical formation in phagocytes, completely prevented apoptosis in the T-cell subset (n=8, p<0.0001). In the presence of mononuclear phagocytes, Ceplene synergized with IL-2 in promoting cell cycle proliferation. Based on these findings, researchers concluded that the phenotype of T-cells with spontaneous reactivity against AML blasts is highly sensitive to oxidants and that by inhibiting oxygen radical formation, Ceplene efficiently protects these cytotoxic lymphocytes from apoptosis in an environment of oxidative stress. In addition, Ceplene was shown to synergize with IL-2 to activate and expand these T-cells.

About Ceplene

Ceplene is EpiCept's registration-stage compound for the treatment of AML. Ceplene is designed to protect lymphocytes responsible for immune-mediated destruction of residual leukemic cells. Laboratory research has demonstrated that Ceplene reduces formation of oxygen radicals from phagocytes, inhibiting NADPH oxidase and protecting IL-2-activated NK-cells and T-cells.

Ceplene Clinical Trial History

A pivotal Phase III study for Ceplene in conjunction with IL-2 was conducted in 11 countries and included 320 randomized patients. This study met its primary endpoint of preventing relapse as shown by increased LFS at three years for AML patients in remission. The data demonstrated that patients with AML in complete remission who received 18 months of treatment with Ceplene plus low dose IL-2 experienced a significantly improved
'/>"/>

SOURCE EpiCept Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. EpiCept Corporation to Present at the 2007 BIO InvestorForum
2. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
3. EpiCept Corporation To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. EpiCept To Host Third Quarter 2007 Conference Call and Webcast on November 7, 2007
5. EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results
6. EpiCept Corporation to Present at the BMO Capital Markets 2007 Focus on Healthcare Conference
7. Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy
8. EpiCept Announces Presentation of New Ceplene(TM) Data at the 49th Annual Meeting of the American Society of Hematology
9. EpiCept Corporation Announces Pricing of Public Offering
10. EpiCept Corporation to Present at The New York Society of Security Analysts 11th Annual Biotech & Specialty Pharma Conference
11. Cleveland Clinic Press Releases Journal-Writing Book Write for Life: Healing Body, Mind, and Spirit Through Journal Writing by Sheppard B. Kominars, Ph.D.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Hamilton, ON (September 22, 2014) South Asians living ... and double the rate of diabetes compared with while ... was published today in the Canadian Medical Association ... http://www.cmajopen.ca/content/2/3/E183.full , One of the fastest-growing ethnic ... million South Asian people living in Canada, comprising about ...
(Date:9/22/2014)... NJ. September 22, 2014. Kessler researchers have published ... 10-week psychoeducational wellness program in people with multiple ... overall mental health, perceived stress, and pain. ... for individuals living with MS: Description and outcomes" ... in the International Journal of MS Care ...
(Date:9/22/2014)... News) -- Two new prescription devices approved by the ... relief for people with migraine headaches who don,t tolerate ... One device -- the Cefaly -- is designed to ... -- is meant to be used when migraines first ... have been looking for alternative migraine treatments. Because these ...
(Date:9/22/2014)... Severe weather can occur with little warning, so ... part of National Preparedness Month, Amica Insurance is offering ... the unexpected:, , Build an emergency supply kit. ... one gallon of water per person per day for at least ... that includes pets so your family knows what to do and ...
(Date:9/22/2014)... New York / Westchester County, NY (PRWEB) September 22, ... Plastic Surgery (NYGPS) has joined the Department of Surgery ... The newly named Mount Sinai Doctors New York Group ... and the lower Hudson Valley access to a team ... plastic surgery techniques. Additionally, C. Andrew Salzberg, MD, ...
Breaking Medicine News(10 mins):Health News:Higher risk of heart disease for South Asians in Canada 2Health News:Noninvasive Devices May Help Migraines, FDA Says 2Health News:Amica Shares Tips for National Preparedness Month 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 3
... RIVERWOODS, Ill., June 10 As more and more employees ... a smaller and smaller percentage of them are actually signing ... the findings of the Spencer,s Benefits Reports 2009 ... COBRA in the 2008 plan year at companies covered by ...
... ARLINGTON, Va., June 10 The Generic Pharmaceutical Association ... and CEO Kathleen Jaeger regarding publication of the Federal ... , , "Today,s report from the FTC ... forward on passage of legislation that brings affordable biogenerics ...
... RIVERSIDE, California and NUREMBERG, Germany, June 10 ,Ziehm Imaging ... and Drug,Administration (FDA) has given 510k clearance for the ... RFD, for marketing and,sales within the United States. Designed ... the Ziehm Vision RFD,mobile C-arm combines the latest flat-panel ...
... Corporation (Nasdaq: KNSY ) is scheduled to present ... 18, 2009. , , Joseph W. Kaufmann, Kensey ... at approximately 9:00 a.m. (ET). To hear the live ... . The presentation materials will also be available on ...
... bacteria,s structure, , WEDNESDAY, June 10 (HealthDay News) -- ... a vacation. , Now, researchers have figured out how ... coli, or ETEC -- are able to make ... or "fimbriae" to attach, or bind, to the intestinal ...
... 2009, the Institute for Quality and Efficiency in Health ... assessment of certain newer antidepressants. The project commissioned by ... the benefit of three agents, reboxetine, mirtazapine and bupropion ... German drug approval status. Interested parties and institutions may ...
Cached Medicine News:Health News:Spencer's Benefits Reports COBRA Survey Finds Recession Takes Hold: More Were Eligible, Fewer Signed Up, Costs Stay High 2Health News:Spencer's Benefits Reports COBRA Survey Finds Recession Takes Hold: More Were Eligible, Fewer Signed Up, Costs Stay High 3Health News:Spencer's Benefits Reports COBRA Survey Finds Recession Takes Hold: More Were Eligible, Fewer Signed Up, Costs Stay High 4Health News:GPhA Statement on FTC Report on 'Follow-on Biologic Drug Competition' 2Health News:GPhA Statement on FTC Report on 'Follow-on Biologic Drug Competition' 3Health News:SVS 2009: Ziehm Imaging Sets a New Standard in Mobile Imaging With the Ziehm Vision RFD 2Health News:SVS 2009: Ziehm Imaging Sets a New Standard in Mobile Imaging With the Ziehm Vision RFD 3Health News:Finding May Lead to Vaccine for Traveler's Diarrhea 2Health News:Preliminary report on antidepressants published 2
(Date:9/22/2014)... September 22, 2014 Final ... 25   The second edition of the ... excited to announce the final nominations for the 2014 ... on the evening of September 25 at The Taj Mahal Palace, ... applicants based on a variety of qualitative and quantitative ...
(Date:9/22/2014)... Sept. 22, 2014  Elusys Therapeutics, Inc. (Elusys), ... infectious disease, today announced it has completed three ... obiltoxaximab (ETI-204). Obiltoxaximab is an anti-toxin in development ... from these studies support the safety and tolerability ... the intended therapeutic dose. The conclusion of these ...
(Date:9/22/2014)... , Sept. 22, 2014  Aethlon Medical, ... therapeutic devices to address infectious disease, cancer and ... Advanced Research Projects Agency (DARPA) has informed the ... to proceed with year four of a five-year ... on September 30, 2011 under DARPA,s Dialysis-Like Therapeutics ...
Breaking Medicine Technology:Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 2Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 5Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 6Aethlon Medical Receives Notice of DARPA Contract Renewal 2Aethlon Medical Receives Notice of DARPA Contract Renewal 3Aethlon Medical Receives Notice of DARPA Contract Renewal 4
... innovative stent allows the physician to intubate the ... with just topical anesthetic drops., ,The SRS is ... in three lengths 25mm, 30mm and 35mm (disposable ... stent is an anchor-shaped head to provide fixation. ...
... or somatomedin-C, is a peptide highly dependent ... promoting activity. IGF-I is transported in serum ... of growth disorders, measurements of IGF-I are ... hormone secretion. A normal plasma or serum ...
... is a high-throughput immunoassay system built around ... 2000 with the important addition of Logic ... to be designed for optimal performance with ... for critical assays such as the cardiac ...
... For The Detection ... Uses Of C-Peptide Measurement:, ... fasting hypoglycemia , Assisting ... diabetes mellitus , Differentiating ...
Medicine Products: